Literature DB >> 30605731

Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results.

Michael A Pulsipher1, Brent R Logan2, Deidre M Kiefer3, Pintip Chitphakdithai3, Marcie L Riches4, J Douglas Rizzo2, Paolo Anderlini5, Susan F Leitman6, James W Varni7, Hati Kobusingye3, RaeAnne M Besser3, John P Miller8, Rebecca J Drexler3, Aly Abdel-Mageed9, Ibrahim A Ahmed10, Edward D Ball11, Brian J Bolwell12, Nancy J Bunin13, Alexandra Cheerva14, David C Delgado15, Christopher C Dvorak16, Alfred P Gillio17, Theresa E Hahn18, Gregory A Hale19, Ann E Haight20, Brandon M Hayes-Lattin21, Kimberly A Kasow22, Michael Linenberger23, Margarida Magalhaes-Silverman24, Shahram Mori25, Vinod K Prasad26, Troy C Quigg27, Indira Sahdev28, Jeffrey R Schriber29, Shalini Shenoy30, William T Tse31, Gregory A Yanik32, Willis H Navarro3, Mary M Horowitz2, Dennis L Confer33, Bronwen E Shaw2, Galen E Switzer34.   

Abstract

Although donation of bone marrow (BM) or peripheral blood stem cells (PBSCs) from children to family members undergoing allogeneic transplantation are well-established procedures, studies detailing levels of pain, symptoms, and long-term recovery are lacking. To address this lack, we prospectively enrolled 294 donors age <18 years at 25 pediatric transplantation centers in North America, assessing them predonation, peridonation, and at 1 month, 6 months, and 1 year postdonation. We noted that 71% of children reported pain and 59% reported other symptoms peridonation, with resolution to 14% and 12% at 1 month postdonation. Both older age (age 13 to 17 years versus younger) and female sex were associated with higher levels of pain peridonation, with the highest rates in older females (57% with grade 2-4 pain and 17% with grade 3-4 pain). Multivariate analyses showed a 4-fold increase in risk for older females compared with males age <13 years (P <.001). At 1 year, 11% of 13- to 17-year-old females reported grade 2-4 pain, compared with 3% of males age 13 to 17 years, 0% of females age <13 years, and 1% of males age <13 years (P = .01). Males and females age 13 to 17 years failed to return to predonation pain levels at 1 year 22% and 23% of the time, respectively, compared with 3% and 10% in males and females age <13 years (P = .002). Our data show that females age 13 to 17 years are at increased risk of grade 2-4 pain at 1 year and >20% of females and males age 13 to 17 years do not return to baseline pain levels by 1 year after BM donation. Studies aimed at decreasing symptoms and improving recovery in older children are warranted.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  BM collection toxicities; Donor safety; PBSC collection toxicities; Stem cell transplantation

Mesh:

Year:  2018        PMID: 30605731      PMCID: PMC6511296          DOI: 10.1016/j.bbmt.2018.12.765

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  23 in total

1.  Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors.

Authors:  M Körbling; K W Chan; P Anderlini; D Seong; A Durett; A Langlinais; D Przepiorka; J Gajewski; P Miller; J Sundberg; P Alilaen; P Bojko; N Mirza; D Claxton; K van Besien; I Khouri; B Andersson; R Mehra; R Champlin
Journal:  Bone Marrow Transplant       Date:  1996-11       Impact factor: 5.483

2.  Experience with marrow harvesting from donors less than two years of age.

Authors:  J Sanders; C D Buckner; W I Bensinger; W Levy; R Chard; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1987-06       Impact factor: 5.483

3.  Pain patterns during adolescence can be grouped into four pain classes with distinct profiles: A study on a population based cohort of 2953 adolescents.

Authors:  S Holden; M S Rathleff; E M Roos; M B Jensen; N Pourbordbari; T Graven-Nielsen
Journal:  Eur J Pain       Date:  2017-12-27       Impact factor: 3.931

4.  Safety and feasibility of granulocyte colony-stimulating factor (G-CSF) primed bone marrow (BM) using three days of G-CSF priming as stem cell source for pediatric allogeneic BM transplantation.

Authors:  Ayad Ahmed Hussein; Shanta Sharma; Abdulhadi Al-Zaben; Haydar Frangoul
Journal:  Pediatr Transplant       Date:  2014-07-07

5.  Parent versus child donor perceptions of the bone marrow donation experience.

Authors:  G E Switzer; J Bruce; G Pastorek; D M Kiefer; H Kobusingye; R Drexler; R A M Besser; D L Confer; M M Horowitz; R J King; B E Shaw; S M van Walraven; L Wiener; W Packman; J W Varni; M A Pulsipher
Journal:  Bone Marrow Transplant       Date:  2017-06-26       Impact factor: 5.483

6.  Health-Related Quality of Life among Pediatric Hematopoietic Stem Cell Donors.

Authors:  Galen E Switzer; Jessica Bruce; Deidre M Kiefer; Hati Kobusingye; Rebecca Drexler; RaeAnne M Besser; Dennis L Confer; Mary M Horowitz; Roberta J King; Bronwen E Shaw; Suzanna M van Walraven; Lori Wiener; Wendy Packman; James W Varni; Michael A Pulsipher
Journal:  J Pediatr       Date:  2016-08-10       Impact factor: 4.406

7.  Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry.

Authors:  Javier de la Rubia; Felipe de Arriba; Cristina Arbona; María J Pascual; Concha Zamora; Andrés Insunza; Dorleta Martínez; Carmen Paniagua; Miguel A Díaz; Miguel A Sanz
Journal:  Haematologica       Date:  2008-04-02       Impact factor: 9.941

8.  Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation.

Authors:  Michael A Pulsipher; Pintip Chitphakdithai; Brent R Logan; Willis H Navarro; John E Levine; John P Miller; Bronwen E Shaw; Paul V O'Donnell; Navneet S Majhail; Dennis L Confer
Journal:  Blood       Date:  2014-04-15       Impact factor: 22.113

Review 9.  Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program.

Authors:  John P Miller; Elizabeth H Perry; Thomas H Price; Charles D Bolan; Chatchada Karanes; Theresa M Boyd; Pintip Chitphakdithai; Roberta J King
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742

10.  High prevalence of daily and multi-site pain--a cross-sectional population-based study among 3000 Danish adolescents.

Authors:  Michael S Rathleff; Ewa M Roos; Jens L Olesen; Sten Rasmussen
Journal:  BMC Pediatr       Date:  2013-11-19       Impact factor: 2.125

View more
  1 in total

1.  Health-Related Quality-of-Life Comparison of Adult Related and Unrelated HSC Donors: An RDSafe Study.

Authors:  Galen E Switzer; Jessica G Bruce; Deidre M Kiefer; Hati Kobusingye; Kaleab Z Abebe; Rebecca Drexler; RaeAnne M Besser; Dennis L Confer; Mary M Horowitz; Roberta J King; Bronwen E Shaw; Marcie Riches; Brandon Hayes-Lattin; Michael Linenberger; Brian Bolwell; Scott D Rowley; Mark R Litzow; Michael A Pulsipher
Journal:  Biol Blood Marrow Transplant       Date:  2020-08-21       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.